• Takeda Pharmaceutical Co Ltd TAK.N reported quarterly adjusted earnings of JPY29.07​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of JPY-15.50. The mean expectation of two analysts for the quarter was for earnings of JPY87.45 per share. Wall Street expected results

• Revenue rose 12.7% to $1.18 trillion from a year ago; analysts expected JPY1.08 trillion.

• Takeda Pharmaceutical Co Ltd shares had fallen by 2.3% this quarter and lost 2.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Takeda Pharmaceutical Co Ltd is $16.30

This summary was machine generated from LSEG data November 1 at 02:59 a.m. UTC. ​All figures in yen unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)